261 related articles for article (PubMed ID: 35943810)
21. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
22. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
23. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Gorman MJ; Patel N; Guebre-Xabier M; Zhu AL; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman KA; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger DA; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
Cell Rep Med; 2021 Sep; 2(9):100405. PubMed ID: 34485950
[TBL] [Abstract][Full Text] [Related]
24. Humoral and cellular immune memory to four COVID-19 vaccines.
Zhang Z; Mateus J; Coelho CH; Dan JM; Moderbacher CR; Gálvez RI; Cortes FH; Grifoni A; Tarke A; Chang J; Escarrega EA; Kim C; Goodwin B; Bloom NI; Frazier A; Weiskopf D; Sette A; Crotty S
Cell; 2022 Jul; 185(14):2434-2451.e17. PubMed ID: 35764089
[TBL] [Abstract][Full Text] [Related]
25. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
Mateo-Urdiales A; Sacco C; Petrone D; Bella A; Riccardo F; Del Manso M; Bressi M; Siddu A; Brusaferro S; Palamara AT; Rezza G; Pezzotti P; Fabiani M;
JAMA Netw Open; 2023 Oct; 6(10):e2336854. PubMed ID: 37792377
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove CA; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jeanes C; Kalra PA; Kyriakidou C; Bradley JM; Munthali C; Minassian AM; McGill F; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Fries L; Cho I; McKnight I; Glenn G; Rivers EJ; Robertson A; Alves K; Smith K; Toback S
Clin Infect Dis; 2023 Feb; 76(3):398-407. PubMed ID: 36210481
[TBL] [Abstract][Full Text] [Related]
27. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults.
Rakshit S; Adiga V; Ahmed A; Parthiban C; Chetan Kumar N; Dwarkanath P; Shivalingaiah S; Rao S; D'Souza G; Dias M; Maguire TJA; Doores KJ; Zoodsma M; Geckin B; Dasgupta P; Babji S; van Meijgaarden KE; Joosten SA; Ottenhoff THM; Li Y; Netea MG; Stuart KD; De Rosa SC; McElrath MJ; Vyakarnam A
Front Immunol; 2022; 13():985938. PubMed ID: 36268023
[TBL] [Abstract][Full Text] [Related]
28. Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein.
Tian X; Zhang Y; He Z; Li S; Yan D; Zhu Z; Wan Y; Wang W
Front Immunol; 2022; 13():875236. PubMed ID: 35514964
[TBL] [Abstract][Full Text] [Related]
29. Immunodominant SARS-CoV-2-specific CD4
Ning J; Wang Q; Chen Y; He T; Zhang F; Chen X; Shi L; Zhai A; Li B; Wu C
J Med Virol; 2023 Apr; 95(4):e28743. PubMed ID: 37185843
[TBL] [Abstract][Full Text] [Related]
30. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
Front Immunol; 2022; 13():942192. PubMed ID: 36275696
[TBL] [Abstract][Full Text] [Related]
31. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.
Parums DV
Med Sci Monit; 2022 Mar; 28():e936523. PubMed ID: 35228506
[TBL] [Abstract][Full Text] [Related]
32. OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines.
Duhen R; Beymer M; Jensen SM; Abbina S; Abraham S; Jain N; Thomas A; Geall AJ; Hu HM; Fox BA; Weinberg AD
Front Immunol; 2022; 13():896310. PubMed ID: 36238275
[TBL] [Abstract][Full Text] [Related]
33. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
[TBL] [Abstract][Full Text] [Related]
34. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
[TBL] [Abstract][Full Text] [Related]
35. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study.
Wang H; Gan M; Wu B; Zeng R; Wang Z; Xu J; Li J; Zhang Y; Cao J; Chen L; Di D; Peng S; Lei J; Zhao Y; Song X; Yuan T; Zhou T; Liu Q; Yi J; Wang X; Cai H; Lei Y; Wen Y; Li W; Chen Q; Wang Y; Long P; Yuan Y; Wang C; Pan A; Wang Q; Gong R; Fan X; Wu T; Liu L
J Med Virol; 2023 Jan; 95(1):e28380. PubMed ID: 36478357
[TBL] [Abstract][Full Text] [Related]
36. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
[TBL] [Abstract][Full Text] [Related]
37. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
[TBL] [Abstract][Full Text] [Related]
38. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.
Chen Y; Yin S; Tong X; Tao Y; Ni J; Pan J; Li M; Wan Y; Mao M; Xiong Y; Yan X; Yang Y; Huang R; Wu C; Shen H
Clin Microbiol Infect; 2022 Mar; 28(3):410-418. PubMed ID: 34715346
[TBL] [Abstract][Full Text] [Related]
39. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination.
Koutsakos M; Lee WS; Wheatley AK; Kent SJ; Juno JA
J Leukoc Biol; 2022 Feb; 111(2):355-365. PubMed ID: 34730247
[TBL] [Abstract][Full Text] [Related]
40. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Front Immunol; 2022; 13():816220. PubMed ID: 35145522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
